EDITORIAL

CONFERENCE REPORTS: ­ 11th European AIDS conference (EACS), 24-27 October 2007, Madrid

• New European guidelines launched
• Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)
• Darunavir once-daily is non-inferior to lopinavir/r in treatment-naïve patients at 48 weeks (Artemis study)
• Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
• Drug interaction studies presented at EACS:
• No interaction between TDF/FTC and nevirapine
• Etravirine reduces maraviroc levels requiring maraviroc dose increase to 600mg BID
• Atazanavir levels not significantly reduced by tenofovir, but higher in Caucasians
• No significant interaction between NucleomaxX and AZT/3TC
• Dose adjustments necessary for immunosuppressants following liver transplant
• No interaction between etravirine and paroxetine
• Tipranavir/r significantly reduces levels of bupropion
• No dose adjustment required when using TMC-278 and atorvastatin
• Efavirenz significantly reduces levels of posaconazole
• Efavirenz dose may not need increasing in low-body weight patients treated wirh rifampicin

TREATMENT ACCESS

• HIV and TB co-infection and treatment charges in the UK
• FDA approval of generic ARVs

ANTIRETROVIRALS

• US adult treatment guidelines updated
• Half-dose Kaletra tablet approved for paediatric use in US

SIDE EFFECTS

• Case report of efavirenz-associated nephrolithiasis
• Yellow card reporting scheme for doctors and patients in the UK

PREGNANCY AND MTCT

• US updates guidelines on use of ARVs during pregnancy
• Perinatal transmission of HIV in England 2002-2005
• Risk factors for in utero or intrapartum mother-to-child Transmission in Thailand

DRUG INTERACTIONS

• New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives
• Recent reviews from HIV-druginteractions.org
• The effect of lopinavir/r on the renal clearance of tenofovir
• T-20 increases tipranavir levels but not hepatotoxicity
• Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment
• Acid reducing agents and protese inhibitors

VACCINE RESEARCH

• Merck HIV vaccine trial is unblinded

OTHER NEWS

• IAS statement on US policy for HIV-positive visitors

ON THE WEB

• Free full text articles
• Online reports

FUTURE MEETINGS

PUBLICATIONS AND SERVICES FROM i-BASE

---

Top | htb | Home | Order & subscribe | Contact | Site map | Access